Several other analysts have also commented on the stock. TheStreet lowered shares of Qiagen from a b- rating to a c+ rating in a research report on Thursday, February 8th. Zacks Investment Research lowered shares of Qiagen from a hold rating to a sell rating in a research report on Monday, December 11th. Cowen restated a hold rating and set a $34.00 price objective on shares of Qiagen in a report on Thursday, December 21st. Morgan Stanley upped their price objective on shares of Qiagen from $38.00 to $39.00 and gave the company an overweight rating in a report on Friday, February 2nd. Finally, Goldman Sachs assumed coverage on shares of Qiagen in a report on Monday, January 29th. They set a buy rating and a $39.00 price objective on the stock. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Qiagen presently has an average rating of Hold and an average price target of $35.33.
Shares of QGEN stock traded down $0.80 during mid-day trading on Thursday, hitting $31.21. 276,723 shares of the stock traded hands, compared to its average volume of 1,080,128. Qiagen has a 52-week low of $27.74 and a 52-week high of $36.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.59.
Qiagen declared that its board has initiated a stock buyback plan on Wednesday, January 31st that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
Institutional investors and hedge funds have recently bought and sold shares of the company. OxFORD Asset Management LLP increased its holdings in shares of Qiagen by 6.7% during the third quarter. OxFORD Asset Management LLP now owns 81,216 shares of the company’s stock valued at $2,558,000 after acquiring an additional 5,116 shares in the last quarter. AXA increased its holdings in Qiagen by 5.0% in the 3rd quarter. AXA now owns 405,798 shares of the company’s stock worth $12,783,000 after buying an additional 19,268 shares during the period. Citadel Advisors LLC increased its holdings in Qiagen by 816.3% in the 4th quarter. Citadel Advisors LLC now owns 1,051,713 shares of the company’s stock worth $32,529,000 after buying an additional 936,936 shares during the period. Myriad Asset Management Ltd. acquired a new position in Qiagen in the 3rd quarter worth approximately $4,747,000. Finally, Acadian Asset Management LLC increased its holdings in Qiagen by 3.4% in the 4th quarter. Acadian Asset Management LLC now owns 412,888 shares of the company’s stock worth $12,770,000 after buying an additional 13,566 shares during the period. Hedge funds and other institutional investors own 62.23% of the company’s stock.
WARNING: “Qiagen (QGEN) Given “Neutral” Rating at DZ Bank” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3335992/qiagen-qgen-given-neutral-rating-at-dz-bank.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.